Through the collaboration, the newly launched MRF Translational Medicine Center will determine the myelin regenerating capabilities of proprietary small molecule compounds from Endece Neural.
The aim of the MRF Translational Medicine Center is to advance potential myelin repair treatment targets toward commercialization to benefit MS patients.
MRF Drug Discovery and Research Operations vice president Jay Tung said by integrating Endece’s innovative approach to remyelination and the resources available at the MRF Translational Medicine Center, they can advance progress towards developing new MS treatments for patients.
Endece Neural is a privately held neurological drug development company, and MRF is a non-profit research organization focused on accelerating the discovery and development of myelin repair therapeutics for MS.